Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03215030 · OUTCOME

Part 3: Health Care Utilization: Number of Participants With at Least One Medical Encounter

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 20.5 months in Part 3

What was measured

Medical encounters included hospitalizations, emergency room stays, or outpatient visits.

Analysis population: The FAS included all participants who received at least 1 dose, even an incomplete dose, of modakafusp alfa, in the Part 3 extension cohorts. Overall number of participants analyzed is the number of participants with data available for analyses.

Groups in this outcome

Part 3 (Dose Extension): Modakafusp Alfa 120 mg

Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Part 3 (Dose Extension): Modakafusp Alfa 240 mg

Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part 3 (Dose Extension): Modakafusp Alfa 120 mg46
Part 3 (Dose Extension): Modakafusp Alfa 240 mg57

Reported measurements

Hospitalizations
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 3 (Dose Extension): Modakafusp Alfa 120 mg29Not reportedNot reportedNot reportedNot reported
Part 3 (Dose Extension): Modakafusp Alfa 240 mg31Not reportedNot reportedNot reportedNot reported
Emergency Room Stays
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 3 (Dose Extension): Modakafusp Alfa 120 mg7Not reportedNot reportedNot reportedNot reported
Part 3 (Dose Extension): Modakafusp Alfa 240 mg8Not reportedNot reportedNot reportedNot reported
All Outpatient Visits
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Part 3 (Dose Extension): Modakafusp Alfa 120 mg10Not reportedNot reportedNot reportedNot reported
Part 3 (Dose Extension): Modakafusp Alfa 240 mg18Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        29
      2. group Id
        OG001
        value
        31
    title
    Hospitalizations
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        7
      2. group Id
        OG001
        value
        8
    title
    Emergency Room Stays
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        10
      2. group Id
        OG001
        value
        18
    title
    All Outpatient Visits
denoms
  1. counts
    1. group Id
      OG000
      value
      46
    2. group Id
      OG001
      value
      57
    units
    Participants
description
Medical encounters included hospitalizations, emergency room stays, or outpatient visits.
groups
  1. description
    Participants received modakafusp alfa 120 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG000
    title
    Part 3 (Dose Extension): Modakafusp Alfa 120 mg
  2. description
    Participants received modakafusp alfa 240 mg, infusion, IV, Q4W, for each 28-day treatment cycle until disease progression or treatment discontinuation.
    id
    OG001
    title
    Part 3 (Dose Extension): Modakafusp Alfa 240 mg
param Type
COUNT_OF_PARTICIPANTS
population Description
The FAS included all participants who received at least 1 dose, even an incomplete dose, of modakafusp alfa, in the Part 3 extension cohorts. Overall number of participants analyzed is the number of participants with data available for analyses.
reporting Status
POSTED
time Frame
Up to 20.5 months in Part 3
title
Part 3: Health Care Utilization: Number of Participants With at Least One Medical Encounter
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice